Garheng Kong, MD, PhD (Observer)
Founder and Managing Partner - HealthQuest Capital
Garheng Kong is the founder and managing partner of HealthQuest Capital. He has over two decades of experience in the healthcare field as an investor, physician, scientist, and engineer.
Dr. Kong’s investments and board directorships have resulted in the IPOs of Cempra (CEMP), Alimera (ALIM), Applied Genetic Technology Corp. (AGTC), Proteon (PRTO), Histogenics (HSGX) and TransEnterix (TRXC). He has also had board roles in many M&A transactions that include Calibra Medical (J&J), Cellective (AstraZeneca), Serenex (Pfizer), Athenix (Bayer), NovaMin (GSK), Aldagen (Cytomedix), Salveo Specialty Pharmacy (Catamaran) and SARCode (Shire). Dr. Kong has been asked to Chair the board of seven companies as well.
Dr. Kong is a member of the board of directors of Laboratory Corporation of America (LabCorp, NYSE:LH) and Duke University Medical Center as well as Alimera Sciences (ALIM), Castle Biosciences, Cempra (CEMP), First Aid Shot Therapy, Histogenics (HSGX), Strongbridge (SBBP), Trice Medical and VirMedica. Dr. Kong’s interests and industry footprint are broad as he also serves on the board of SEBIO, Corporate Chaplains of America, Cure Network Ventures, and advises IDEO Palo Alto and numerous industry groups. He has also served on the Duke Medical Center Institutional Review Board (IRB) and as faculty at the Duke Fuqua School of Business as a senior scholar.
Dr. Kong received two undergraduate degrees, in chemical engineering and biological sciences, from Stanford University, which he attended on an athletic scholarship. He then earned his MD, PhD and MBA from Duke University, graduating at the top of his class in each instance. His early career included stints at GlaxoSmithKline, McKinsey & Co. and medical device startup TherOx. Dr. Kong has been founder and CEO of two successful biopharma companies (Cellective and Viamet). Prior to HealthQuest, he was a general partner at Intersouth Partners and a general partner at Sofinnova Ventures.